Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)

PHASE3CompletedINTERVENTIONAL
Enrollment

273

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

June 7, 2019

Study Completion Date

June 7, 2019

Conditions
Multiple Myeloma
Interventions
DRUG

Lenalidomide

In BMT CTN 0702, maintenance therapy with lenalidomide started at 10 mg daily for three months and increased to 15 mg daily. The duration of maintenance was three years in all treatment arms. Lenalidomide will be administered initially at the patient's last documented dose prior to discontinuation of BMT CTN 0702 lenalidomide maintenance therapy. Cycle duration is 28 days. Patients will continue lenalidomide until disease progression, or discontinuation due to toxicity, death, or withdrawal from the study.

Trial Locations (42)

10029

Mount Sinai Medical Center, New York

10174

Memorial Sloan-Kettering Cancer Center, New York

11042

North Shore University Hospital, Lake Success

14263

Roswell Park Cancer Center, Buffalo

17033

Penn State College of Medicine, The Milton S. Hershey Medical Center, Hershey

19104

University of Pennsylvania Cancer Center, Philadelphia

26506

West Virginia University Hospital, Morgantown

27157

Wake Forest University Health Sciences, Winston-Salem

27705

Duke University Medical Center, Durham

30342

BMT Group of Georgia (Northside Hospital), Atlanta

32610

University of Florida College of Medicine, Gainesville

33624

University of Miami, Miami

H. Lee Moffitt Cancer Center, Tampa

37203

Sarah Cannon Blood & Marrow Transplant Program, Nashville

43210

Ohio State/Arthur G. James Cancer Hospital, Columbus

45236

Jewish Hospital BMT Program, Cincinnati

48201

Karmanos Cancer Institute/BMT, Detroit

53211

Medical College of Wisconsin, Milwaukee

55455

University of Minnesota, Minneapolis

60612

Rush University Medical Center, Chicago

63110

Washington University, Barnes Jewish Hospital, St Louis

66160

University of Kansas Hospital, Kansas City

71130

Louisiana State University Health Sciences Center, Shreveport

73104

University of Oklahoma Medical Center, Oklahoma City

75390

University of Texas Southwestern Medical Center, Dallas

77030

University of Texas/MD Anderson CRC, Houston

78229

Texas Transplant Institute, San Antonio

80218

Colorado Blood Cancer Institute, Denver

85724

Arizona Cancer Center, Tucson

92093

University of California, San Diego Medical Center, La Jolla

94305

Stanford Hospital and Clinics, Stanford

91010-3000

City of Hope National Medical Center, Duarte

02114

DFCI, Brigham and Womens Hospital, Boston

48105-2967

University of Michigan Medical Center, Ann Arbor

68198-7680

University of Nebraska Medical Center, Omaha

07601

Hackensack University Medical Center, Hackensack

27599-7305

University of North Carolina Hospital at Chapel Hill, Chapel Hill

44106-5061

University Hospitals of Cleveland/Case Western, Cleveland

97239-3098

Oregon Health & Science University, Portland

37232-8210

Vanderbilt University Medical Center, Nashville

98109-1024

Fred Hutchinson Cancer Research Center, Seattle

53792-5156

University of Wisconsin Hospital & Clinics, Madison

All Listed Sponsors
collaborator

Blood and Marrow Transplant Clinical Trials Network

NETWORK

collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Marrow Donor Program

OTHER

lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT02322320 - Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT) | Biotech Hunter | Biotech Hunter